The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis

Michael Hiligsmann; Jean-Yves Reginster; Stuart Silverman

doi:10.18553/jmcp.2020.26.3.334

The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis

Michael Hiligsmann^*
, Jean-Yves Reginster
, Stuart Silverman

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Merck Sharp and Dohme, Rottapharm, Teijin, Teva, Analis, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Meda, Bristol Myers Squibb, Pfizer, Organon, Therabel, Boehringer, Chiltern, and Galapagos. Silverman has received grant support from Amgen, Radius, and Lilly; consulting fees from Amgen and Radius; has served on scientific advisory boards for Lilly and Amgen; and has served on speakers bureaus for Amgen, Lilly, and Radius.

Original language	English
Pages (from-to)	334-335
Number of pages	3
Journal	Journal of managed care & specialty pharmacy
Volume	26
Issue number	3
DOIs	https://doi.org/10.18553/jmcp.2020.26.3.334
Publication status	Published - Mar 2020

Access to Document

10.18553/jmcp.2020.26.3.334

https://pmc.ncbi.nlm.nih.gov/articles/PMC10390972/pdf/jmcp.2020.26.3.334.pdfLicence: Other

Cite this

@article{f7eb5167963d4bf296feb487bb4c55da,

title = "The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis",

abstract = "No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Merck Sharp and Dohme, Rottapharm, Teijin, Teva, Analis, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Meda, Bristol Myers Squibb, Pfizer, Organon, Therabel, Boehringer, Chiltern, and Galapagos. Silverman has received grant support from Amgen, Radius, and Lilly; consulting fees from Amgen and Radius; has served on scientific advisory boards for Lilly and Amgen; and has served on speakers bureaus for Amgen, Lilly, and Radius.",

author = "Michael Hiligsmann and Jean-Yves Reginster and Stuart Silverman",

note = "Funding Information: No outside funding supported the writing of this letter. Ollendorf reports advisory board and consulting fees from DBV Technologies, EMD Serano, Gerson Lehman Group, and Sarepta Therapeutics, unrelated to the content of this research letter. Naci reports a grant from the Commonwealth Fund, unrelated to the content of this letter. The other authors have nothing to disclose.",

year = "2020",

month = mar,

doi = "10.18553/jmcp.2020.26.3.334",

language = "English",

volume = "26",

pages = "334--335",

journal = "Journal of managed care \& specialty pharmacy",

issn = "2376-0540",

publisher = "Academy of Managed Care Pharmacy (AMCP)",

number = "3",

}

The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis. / Hiligsmann, Michael; Reginster, Jean-Yves; Silverman, Stuart.
In: Journal of managed care & specialty pharmacy, Vol. 26, No. 3, 03.2020, p. 334-335.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis

AU - Hiligsmann, Michael

AU - Reginster, Jean-Yves

AU - Silverman, Stuart

N1 - Funding Information: No outside funding supported the writing of this letter. Ollendorf reports advisory board and consulting fees from DBV Technologies, EMD Serano, Gerson Lehman Group, and Sarepta Therapeutics, unrelated to the content of this research letter. Naci reports a grant from the Commonwealth Fund, unrelated to the content of this letter. The other authors have nothing to disclose.

PY - 2020/3

Y1 - 2020/3

N2 - No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Merck Sharp and Dohme, Rottapharm, Teijin, Teva, Analis, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Meda, Bristol Myers Squibb, Pfizer, Organon, Therabel, Boehringer, Chiltern, and Galapagos. Silverman has received grant support from Amgen, Radius, and Lilly; consulting fees from Amgen and Radius; has served on scientific advisory boards for Lilly and Amgen; and has served on speakers bureaus for Amgen, Lilly, and Radius.

AB - No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Merck Sharp and Dohme, Rottapharm, Teijin, Teva, Analis, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Meda, Bristol Myers Squibb, Pfizer, Organon, Therabel, Boehringer, Chiltern, and Galapagos. Silverman has received grant support from Amgen, Radius, and Lilly; consulting fees from Amgen and Radius; has served on scientific advisory boards for Lilly and Amgen; and has served on speakers bureaus for Amgen, Lilly, and Radius.

U2 - 10.18553/jmcp.2020.26.3.334

DO - 10.18553/jmcp.2020.26.3.334

M3 - Comment/Letter to the editor

C2 - 32105170

SN - 2376-0540

VL - 26

SP - 334

EP - 335

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

IS - 3

ER -

The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis

Abstract

Access to Document

Fingerprint

Cite this